Za zdravnike

10 najboljših priporočil

Ne priporočaj, predpisuj ali uporabljaj zdravil proti kašlju pri otrocih.

Ne uporabljaj bronhodilatatorjev in/ali kortikosteroidov pri dojenčkih z bronhiolitisom.

Pri otrocih s težkimi okužbami preidi iz
intravenskega (IV) na peroralno antibiotično zdravljenje takoj, ko se klinično stanje izboljša.

Izogibaj se rutinski uporabi antibiotikov pri zdravljenju akutnega vnetja srednjega ušesa pri otrocih.

Ne uvajaj antibiotične terapije pri novorojenčkih brez kliničnih znakov sepse.

Ne podaljšuj hospitalizacije pri neprizadetih dojenčkih z vročino, kjer ostajajo hemokulture po 24 do 36 urah sterilne in je možno opraviti kontrolni pregled.

Ne podaljšuj antibiotične terapije pri novorojenčkih po 36 do 48 urah brez jasnega suma na neonatalno sepso.

Ne izvajaj IgE testov v obliki velikih panelov za prehrambene alergene brez anamneze, skladne z alergijo na hrano.

Pri otrocih z vročino in znaki okužbe dihal, ki so starejši od 2 mesecev, rutinsko naročanje urinokulture ni potrebno.

Izogibaj se rutinski uporabi zaviralcev protonske črpalke in motilitetnih zdravil pri dojenčkih z gastroezofagealnim refluksom.

Zdravila proti kašlju

Bronhiolitis

IV-antibiotik-trajanje

Akutno vnetje srednjega ušesa-antibiotik

Antibiotik pri novorojenčkih-uvedba

Hospitalizacija pri dojenčkih z vročino

Antibiotik pri novorojenčkih-trajanje

Urinokultura

Gastroezofagealni refluks

Created with Raphaël 2.1.0

Your Enquiries Are Welcome

We will respond to you by Email

""
 

Core-MD Project

Coordinating Research and Evidence for Medical Devices (CORE-MD)

New ways to test high-risk medical devices.

 

Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.


It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.

EAP Representative: